Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

anika therapeut - ANIK

ANIK

Close Chg Chg %
10.30 0.16 1.55%

Closed Market

10.46

+0.16 (1.55%)

Volume: 139.51K

Last Updated:

Feb 6, 2026, 4:00 PM EDT

Trade Now

Company Overview: anika therapeut - ANIK

ANIK Key Data

Open

$10.40

 Day Range

10.20 - 10.54

52 Week Range

7.90 - 18.35

 Market Cap

$153.87M

Shares Outstanding

14.42M

 Public Float

13.85M

Beta

0.43

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$2.28

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

160.47K

  

ANIK Performance

1 Week
 
 13.33%
 
1 Month
 
 9.87%
 
3 Months
 
 6.19%
 
1 Year
 
 -41.20%
 
5 Years
 
 -72.39%
 

ANIK Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 2
Full Ratings ➔

About anika therapeut - ANIK

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company's main focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and its products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika Therapeutics was founded in 1992 and is headquartered in Bedford, MA.

ANIK At a Glance

Anika Therapeutics, Inc.
32 Wiggins Avenue
Bedford, Massachusetts 01730
Phone 1-781-457-9000 Revenue 119.91M
Industry Medical Specialties Net Income -56,385,000.00
Sector Health Technology Employees 288
Fiscal Year-end 12 / 2025
View SEC Filings

ANIK Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.021
Price to Book Ratio 1.541
Price to Cash Flow Ratio 44.85
Enterprise Value to EBITDA 362.199
Enterprise Value to Sales 1.773
Total Debt to Enterprise Value 0.122

ANIK Efficiency

Revenue/Employee 416,343.75
Income Per Employee -195,781.25
Receivables Turnover 5.082
Total Asset Turnover 0.478

ANIK Liquidity

Current Ratio 4.877
Quick Ratio 3.855
Cash Ratio 2.387

ANIK Profitability

Gross Margin 63.381
Operating Margin -4.254
Pretax Margin -2.305
Net Margin -47.024
Return on Assets -3.517
Return on Equity -4.821
Return on Total Capital -4.907
Return on Invested Capital -4.232

ANIK Capital Structure

Total Debt to Total Equity 16.84
Total Debt to Total Capital 14.413
Total Debt to Total Assets 12.026
Long-Term Debt to Equity 15.595
Long-Term Debt to Total Capital 13.347
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Anika Therapeut - ANIK

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
147.79M 156.24M 166.66M 119.91M
Sales Growth
+13.29% +5.71% +6.67% -28.05%
Cost of Goods Sold (COGS) incl D&A
64.85M 62.66M 63.57M 43.91M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
15.99M 16.35M 14.23M 5.69M
Depreciation
8.19M 8.55M 6.43M 5.01M
Amortization of Intangibles
7.80M 7.80M 7.80M 678.00K
COGS Growth
+5.57% -3.38% +1.46% -30.93%
Gross Income
82.94M 93.58M 103.09M 76.00M
Gross Income Growth
+20.16% +12.82% +10.16% -26.28%
Gross Profit Margin
+56.12% +59.89% +61.85% +63.38%
2021 2022 2023 2024 5-year trend
SG&A Expense
100.82M 112.98M 115.54M 81.10M
Research & Development
26.73M 28.18M 32.69M 25.54M
Other SG&A
74.10M 84.79M 82.85M 55.55M
SGA Growth
+31.02% +12.05% +2.27% -29.81%
Other Operating Expense
- - - -
-
Unusual Expense
- - (20.50M) 75.19M
-
EBIT after Unusual Expense
2.62M (19.40M) (87.64M) (5.10M)
Non Operating Income/Expense
(188.00K) 654.00K 2.31M 2.34M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
2.43M (18.75M) (85.33M) (2.76M)
Pretax Income Growth
+108.48% -872.39% -355.17% +96.76%
Pretax Margin
+1.64% -12.00% -51.20% -2.31%
Income Tax
(1.71M) (3.89M) (2.66M) 6.06M
Income Tax - Current - Domestic
(141.00K) 1.29M 3.46M 5.41M
Income Tax - Current - Foreign
167.00K 96.00K 312.00K 421.00K
Income Tax - Deferred - Domestic
- (979.00K) (4.50M) (6.46M)
Income Tax - Deferred - Foreign
(754.00K) (774.00K) 29.00K 229.00K
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
4.13M (14.86M) (82.67M) (8.83M)
Minority Interest Expense
- - - -
-
Net Income
4.13M (14.86M) (82.67M) (8.83M)
Net Income Growth
+117.24% -459.43% -456.34% +89.32%
Net Margin Growth
+2.80% -9.51% -49.60% -7.36%
Extraordinaries & Discontinued Operations
- - - (47.56M)
-
Discontinued Operations
- - - (47.56M)
-
Net Income After Extraordinaries
4.13M (14.86M) (82.67M) (56.39M)
Preferred Dividends
- - - -
-
Net Income Available to Common
4.13M (14.86M) (82.67M) (56.38M)
EPS (Basic)
0.2871 -1.0205 -5.6405 -3.8302
EPS (Basic) Growth
+117.03% -455.45% -452.72% +32.09%
Basic Shares Outstanding
14.40M 14.56M 14.66M 14.72M
EPS (Diluted)
0.2825 -1.0205 -5.6405 -3.8302
EPS (Diluted) Growth
+116.75% -461.24% -452.72% +32.09%
Diluted Shares Outstanding
14.63M 14.56M 14.66M 14.72M
EBITDA
(1.89M) (3.05M) 1.78M 587.00K
EBITDA Growth
-126.78% -60.99% +158.60% -67.11%
EBITDA Margin
-1.28% -1.95% +1.07% +0.49%

Snapshot

Average Recommendation BUY Average Target Price 16.00
Number of Ratings 2 Current Quarters Estimate -0.175
FY Report Date 03 / 2026 Current Year's Estimate -0.485
Last Quarter’s Earnings -0.125 Median PE on CY Estimate N/A
Year Ago Earnings -0.615 Next Fiscal Year Estimate 0.35
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 2 2 2 1
Mean Estimate -0.18 -0.11 -0.49 0.35
High Estimates 0.00 0.07 0.26 0.35
Low Estimate -0.35 -0.29 -1.23 0.35
Coefficient of Variance -141.42 -231.42 -217.23 N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 2
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Anika Therapeut - ANIK

Date Name Shares Transaction Value
Mar 14, 2025 Cheryl Renee Blanchard President, CEO, Director; Director 197,015 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 14, 2025 Cheryl Renee Blanchard President, CEO, Director; Director 184,340 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.79 per share 3,095,068.60
Mar 14, 2025 Cheryl Renee Blanchard President, CEO, Director; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 14, 2025 David B. Colleran EVP, General Counsel, Corp Sec 45,649 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 14, 2025 David B. Colleran EVP, General Counsel, Corp Sec 43,399 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.79 per share 728,669.21
Mar 14, 2025 David B. Colleran EVP, General Counsel, Corp Sec N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 14, 2025 Anne M. Nunes SVP, Chief Operations Officer 18,837 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 14, 2025 Anne M. Nunes SVP, Chief Operations Officer 18,085 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.79 per share 303,647.15
Mar 14, 2025 Anne M. Nunes SVP, Chief Operations Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Anika Therapeut in the News